2026-07-22T03:36:54Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/83562024-11-30T00:46:00Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Horne, Hisani N author Oh, Hannah author Sherman, Mark E author Palakal, Maya author Hewitt, Stephen M author Schmidt, Marjanka K author Milne, Roger L author Hardisson, David author Benitez, Javier author Blomqvist, Carl author Bolla, Manjeet K author Brenner, Hermann author Chang-Claude, Jenny author Cora, Renata author Couch, Fergus J author Cuk, Katarina author Devilee, Peter author Easton, Douglas F author Eccles, Diana M author Eilber, Ursula author Hartikainen, Jaana M author Heikkilä, Päivi author Holleczek, Bernd author Hooning, Maartje J author Jones, Michael author Keeman, Renske author Mannermaa, Arto author Martens, John W M author Muranen, Taru A author Nevanlinna, Heli author Olson, Janet E author Orr, Nick author Perez, Jose I A author Pharoah, Paul D P author Ruddy, Kathryn J author Saum, Kai-Uwe author Schoemaker, Minouk J author Seynaeve, Caroline author Sironen, Reijo author Smit, Vincent T H B M author Swerdlow, Anthony J author Tengström, Maria author Thomas, Abigail S author Timmermans, A Mieke author Tollenaar, Rob A E M author Troester, Melissa A author van Asperen, Christi J author van Deurzen, Carolien H M author Van Leeuwen, Flora F author Van't Veer, Laura J author García-Closas, Montserrat author Figueroa, Jonine D author 2018-04-26 E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes. Sci Rep. 2018 ;8(1):6574. 10.1038/s41598-018-23733-4 2045-2322 2045-2322 Scientific reports 29700408 http://hdl.handle.net/20.500.12105/8356 E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium